A series of changes in genes related to DNA damage and repair, such as ATM, RB1, FANCC, and ERCC2, have been shown to be associated with the prognosis of MIBC after chemotherapy.6,38,39 Although research is still lacking on these related genes and prognosis in immunotherapeutic regimens, this suggests that, in the future, for MIBC patients who wish to undergo bladder-preserving treatment, the genetic changes in the tumor can be detected to select appropriate treatment options, thereby achieving personalized treatment and precision medicine. The gene discussed is FANCC; the disease is neoplasm.